Ascendis Pharma (ASND) AI Stock Analysis

• Market Cap: $12.83B
• Dividend Yield: N/A
• Average Volume (3M): 523.86K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.65
• Revenue Growth: 103.32%
• EPS Growth: 47.55%
• Country: US
• Employees: 1,017
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.16
• Shares Outstanding: 61,151,463
• 10 Day Avg. Volume: 755,914
• 30 Day Avg. Volume: 523,859
• PEG Ratio: 0.86
• Price to Book (P/B): -72.81
• Price to Sales (P/S): 21.17
• P/FCF Ratio: -25.02
• Enterprise Value/Market Cap: 0.97
• Enterprise Value/Revenue: 19.18
• Enterprise Value/Gross Profit: 22.10
• Enterprise Value/Ebitda: -93.13
• 1Y Price Target: $259.71
• Price Target Upside: 22.31% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 15
• EPS Forecast (FY): -3.67
• Revenue Forecast (FY): $806.36M

• Rating: 46 Neutral
• Price Target: $195.00 ▼(-8.16% Downside)

Ascendis Pharma's overall stock score is primarily influenced by its financial performance challenges, including high leverage and negative cash flows. While the earnings call provided positive insights into revenue growth and regulatory progress, the stock's valuation remains unattractive due to ongoing losses. Technical indicators suggest a lack of strong momentum, further impacting the score.

Positive Factors

Revenue Growth

Significant revenue growth indicates strong market demand and successful product launches, supporting long-term financial health and expansion.

Regulatory Approvals

Regulatory approvals enhance market access and credibility, paving the way for increased sales and competitive positioning in key markets.

Product Pipeline

A robust pipeline with priority reviews suggests potential for future growth and innovation, securing long-term revenue streams and market leadership.

Negative Factors

High Leverage

High leverage poses financial risks, limiting flexibility and increasing vulnerability to economic downturns, potentially impacting long-term stability.

Negative Cash Flows

Persistent negative cash flows highlight operational inefficiencies and may strain resources, affecting the company's ability to invest in growth initiatives.

Profitability Challenges

Ongoing profitability issues indicate operational challenges, which could hinder sustainable growth and require strategic adjustments to improve margins.

Ascendis Pharma Business Overview & Revenue Model

Company Description

Ascendis Pharma is a biopharmaceutical company focused on innovative therapies for rare diseases and other serious conditions. The company operates primarily in the endocrinology sector and is known for its transformative product development approach, particularly its TransCon technology platform. Ascendis Pharma's core products include therapies aimed at growth hormone deficiencies and other endocrine disorders, leveraging its proprietary drug delivery methods to enhance patient outcomes.

How the Company Makes Money

Ascendis Pharma generates revenue primarily through the commercialization of its biopharmaceutical products, which include approved therapies and those in various stages of clinical trials. The company earns income from product sales, licensing agreements, and partnerships with other pharmaceutical companies for research and development collaborations. Significant revenue streams include sales from its flagship products as well as milestone payments and royalties from licensing agreements. Partnerships with larger pharmaceutical firms also contribute to its earnings by providing funding for clinical development and potential future sales of co-developed products.

Ascendis Pharma Financial Statement Overview

Summary

Ascendis Pharma shows strong revenue growth but struggles with profitability and financial stability due to high leverage and negative equity. The cash flow situation is challenging, with negative operating and free cash flows, highlighting the need for improved cash management and operational efficiency.

Income Statement

Ascendis Pharma shows strong revenue growth with a 31.75% increase in TTM, indicating positive momentum. However, the company faces significant profitability challenges, with a negative net profit margin of -55.25% and negative EBIT and EBITDA margins, reflecting ongoing operational losses.

Balance Sheet

The balance sheet reveals high leverage with a negative debt-to-equity ratio due to negative equity, posing financial stability risks. The return on equity is also negative, indicating inefficiencies in generating returns on shareholders' investments.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, although the free cash flow to net income ratio is slightly above 1, suggesting some efficiency in cash usage relative to net losses. However, the negative free cash flow growth rate indicates deteriorating cash flow conditions.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	646.55M	363.64M	266.72M	51.17M	7.78M	6.95M
Gross Profit	561.21M	319.38M	222.32M	39.04M	4.25M	6.95M
EBITDA	-133.16M	-290.02M	-411.17M	-529.18M	-364.64M	-407.81M
Net Income	-232.94M	-378.08M	-481.45M	-583.19M	-383.58M	-418.95M
Balance Sheet
Total Assets	1.15B	1.18B	825.59M	1.09B	1.08B	979.79M
Cash, Cash Equivalents and Short-Term Investments	539.09M	559.54M	399.44M	735.46M	682.06M	718.79M
Total Debt	813.65M	856.62M	743.06M	617.57M	209.92M	91.97M
Total Liabilities	1.33B	1.29B	971.28M	826.39M	201.29M	141.08M
Stockholders Equity	-174.07M	-105.71M	-145.70M	263.35M	883.63M	838.71M
Cash Flow
Free Cash Flow	-112.15M	-307.62M	-469.80M	-510.19M	-441.88M	-293.10M
Operating Cash Flow	-106.68M	-306.20M	-467.36M	-495.70M	-417.65M	-271.55M
Investing Cash Flow	-5.48M	6.88M	286.47M	61.73M	-110.58M	-291.20M
Financing Cash Flow	27.90M	443.93M	134.29M	396.77M	351.39M	602.65M

Ascendis Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 212.33
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ASND, the sentiment is Positive. The current price of 212.33 is above the 20-day moving average (MA) of 205.84, above the 50-day MA of 204.13, and above the 200-day MA of 178.19, indicating a bullish trend. The MACD of 2.18 indicates Negative momentum. The RSI at 57.07 is Neutral, neither overbought nor oversold. The STOCH value of 45.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ASND.

Ascendis Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UTHR	79 Outperform	$21.03B	18.51	20.04%	―	13.50%	17.16%
EXEL	76 Outperform	$11.85B	18.61	30.56%	―	9.93%	54.33%
BMRN	73 Outperform	$10.67B	20.80	9.07%	―	12.31%	60.21%
MDGL	56 Neutral	$13.56B	―	-41.22%	―	864.21%	48.12%
BBIO	55 Neutral	$13.88B	―	―	―	62.46%	-73.59%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ASND	46 Neutral	$12.83B	―	―	―	103.32%	47.55%

Ascendis Pharma Corporate Events

Ascendis Pharma Grants Warrants to Employees in Strategic Move

On November 11, 2025, Ascendis Pharma’s board of directors granted 41,220 warrants to select employees, allowing them to subscribe to ordinary shares at an exercise price of $201.16 per share. This move, which includes amending the company’s Articles of Association, signifies a strategic effort to incentivize and retain key personnel, potentially impacting the company’s operational dynamics and stakeholder interests.

Ascendis Pharma Reports Q3 2025 Financial Results with Revenue Growth

Ascendis Pharma released its unaudited condensed consolidated interim financial statements for the period ending September 30, 2025. The company reported a net loss of EUR 60.989 million for the three months ended September 30, 2025, compared to a net loss of EUR 99.198 million in the same period in 2024. Despite the loss, the company showed an increase in revenue to EUR 213.634 million from EUR 57.833 million in the previous year, indicating a significant growth in sales. This financial update may impact the company’s market positioning by highlighting its revenue growth despite ongoing losses, which could influence investor sentiment and strategic decisions moving forward.

Ascendis Pharma Achieves Strong Q3 2025 Financial Results Amid Product Expansion

Ascendis Pharma reported strong financial results for the third quarter of 2025, with total revenue reaching €213.6 million, a significant increase from the previous year. The company achieved an operating profit of €11.0 million, driven by the successful global launch of YORVIPATH and the continued uptake of SKYTROFA. The company is advancing its pipeline with TransCon CNP under FDA priority review for treating achondroplasia in children, with a decision expected by the end of November 2025. Ascendis is also expanding its product labels and conducting trials to support further growth, indicating a positive outlook for future innovation and market expansion.

Ascendis Pharma Launches Expanded SKYTROFA Dosing in U.S.

On October 22, 2025, Ascendis Pharma announced the commercial availability of SKYTROFA (TransCon hGH) in the United States, expanding its dosing options for adults with growth hormone deficiency. This development marks a significant step in the company’s efforts to enhance its product offerings in the endocrinology market, potentially improving its competitive positioning and providing more options for patients and healthcare providers.

Ascendis Pharma Grants Employee Warrants to Boost Engagement

On October 14, 2025, Ascendis Pharma’s board of directors granted 31,710 warrants to certain employees, allowing them to subscribe for ordinary shares at an exercise price of $208.71 per share. This move, which amends the company’s Articles of Association, is part of their strategy to incentivize employees and aligns with their broader market objectives. The grant leaves 1,794,273 shares available for future warrant issuance, reflecting the company’s ongoing commitment to employee engagement and retention.

Ascendis Pharma Submits EMA Application for Achondroplasia Treatment

On October 8, 2025, Ascendis Pharma announced the submission of a Marketing Authorisation Application to the European Medicines Agency for TransCon CNP, a treatment for children with achondroplasia. This investigational prodrug aims to provide continuous inhibition of the FGFR3 pathway, potentially improving the quality of life for individuals with this rare genetic condition.

Ascendis Pharma Closes Warrant Exercise Window, Boosts Share Capital

On September 29, 2025, Ascendis Pharma A/S closed an exercise window for its outstanding warrants, resulting in an increase of its share capital by nominal DKK 543,748. This move, which involved the issuance of 543,748 ordinary shares, reflects the company’s ongoing efforts to strengthen its financial position and potentially enhance its market presence.

Ascendis Pharma Grants Employee Warrants to Boost Engagement

On September 9, 2025, Ascendis Pharma’s board of directors granted 33,890 warrants to certain employees, allowing them to subscribe for ordinary shares at an exercise price of $202.91 per share. This move is part of the company’s strategy to incentivize employees and align their interests with company growth, with 25% of the warrants vesting after one year and the rest vesting monthly over the following three years. This grant leaves 1,825,983 shares available for future warrant grants, potentially impacting the company’s share capital structure and employee retention strategies.